Acenocoumarol

ApprovedSmall molecule

Roche

Acenocoumarol is one of 83 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Venous ThrombosisActive, not recruiting

Pulmonary EmbolismActive, not recruiting

StrokePreclinical

Active, not recruiting

Venous ThrombosisApproved

Active, not recruiting

Pulmonary EmbolismApproved

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Acenocoumarol

Roche

Approved

1 2

Activase

Roche

Preclinical

19 3

Zometa

Pfizer

Preclinical

1 4

Proamatine

Pradaxa

3 6

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Haldol

DDePuy Orthopaedics

Preclinical

1 8

Zantac 150

CChattem

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Carbidopa-Levodopa

Neurocrine Biosciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic1 trial

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Completed· Roche logo

Roche·Phase 1·NCT01851824·9 enrolled

Anticoagulation1 trial

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

Completed·MMaastricht University·N/A·NCT00512928·20 enrolled

Venous thrombosis1 trial

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT00689520·241 enrolled

Stroke1 trial

Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)

Unknown status·HHospital Mutua de Terrassa··NCT02742480·500 enrolled

Anticoagulant1 trial

Start or STop Anticoagulants Randomised Trial (SoSTART)

Completed·UUniversity of Edinburgh·Phase 3·NCT03153150·203 enrolled

3 more indications

Thrombosis1 trial

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)

Unknown status·SSemmelweis University Heart and Vascular Center·Phase 4·NCT02826200·200 enrolled

Pulmonary Embolism1 trial

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

Completed·—·Phase 4·NCT00711308·102 enrolled

Rivaroxaban1 trial

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Completed·IInstituto Mexicano del Seguro Social·Phase 2/3·NCT05515120·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Acenocoumarol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acenocoumarol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acenocoumarol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

Acenocoumarol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic1 trial

Anticoagulation1 trial

Venous thrombosis1 trial

Stroke1 trial

Anticoagulant1 trial

Thrombosis1 trial

Pulmonary Embolism1 trial

Rivaroxaban1 trial

References

Drug Info

Quick Facts

Related News